Skip to content

Study · Not a test of the peptide alone · 2026

4 results

Topology-Controlled PEGylation Enhances Renal Accumulation of Therapeutic Peptide for Treating Ischemia-Reperfusion Injury.

Wen Y, Zhao Z, Zheng X, Zhao Y, Sun S, Mi S, Cheng X, Lu X, Wang Q

Nano letters25 Jun 2026

PMID42358073 (opens in a new tab)DOI10.1021/acs.nanolett.6c01908 (opens in a new tab)PepBankPUB-42358073
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics

    The lead multiarm PEG-SS31 conjugate produced markedly enhanced renal accumulation relative to free SS31 and alternative architectures.

    In plain wordsA PEG-SS31 conjugate reached the kidney more than free SS31 and other PEG designs.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseRenal accumulation
    Study

    mousen: not reported in source

    murine kidney ischemia-reperfusion injury model
    Comparator
    Free SS31 and alternative PEG architectures
    Outcome group
    Pharmacokinetics · Kidney and urinary

    Source sentences

    Summary
    produces markedly enhanced renal accumulation relative to free SS31 and alternative architectures
    1 context sentence
    Summary · context
    Here, we prepared multiarm PEG-SS31 conjugates with controlled arm number and total PEG molecular weight.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In a murine model of kidney ischemia-reperfusion injury, the lead PEG-SS31 conjugate yielded superior renoprotection.

    In plain wordsIn mice with kidney injury, a PEG-SS31 conjugate protected the kidney better.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseRenoprotection
    Study

    mousen: not reported in source

    murine kidney ischemia-reperfusion injury model
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    yields superior renoprotection in a murine IRI model with reduced tubular injury and apoptosis.
    1 context sentence
    Summary · context
    Here, we prepared multiarm PEG-SS31 conjugates with controlled arm number and total PEG molecular weight.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  3. 03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In a murine model of kidney ischemia-reperfusion injury, the lead PEG-SS31 conjugate reduced tubular injury.

    In plain wordsIn mice with kidney injury, a PEG-SS31 conjugate reduced damage to kidney tubules.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseTubular injury
    Study

    mousen: not reported in source

    murine kidney ischemia-reperfusion injury model
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    yields superior renoprotection in a murine IRI model with reduced tubular injury and apoptosis.
    1 context sentence
    Summary · context
    Here, we prepared multiarm PEG-SS31 conjugates with controlled arm number and total PEG molecular weight.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  4. 04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In a murine model of kidney ischemia-reperfusion injury, the lead PEG-SS31 conjugate reduced apoptosis.

    In plain wordsIn mice with kidney injury, a PEG-SS31 conjugate reduced cell death in the kidney.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseApoptosis
    Study

    mousen: not reported in source

    murine kidney ischemia-reperfusion injury model
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    yields superior renoprotection in a murine IRI model with reduced tubular injury and apoptosis.
    1 context sentence
    Summary · context
    Here, we prepared multiarm PEG-SS31 conjugates with controlled arm number and total PEG molecular weight.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.